This story is part of STAT’s quarterly series Something Ventured, which looks at early-stage startups. You can read the earlier stories in the series here.
Private biotech companies tend to be, well, private. That might explain why so many barely make a public peep after raising millions of dollars from venture capital firms. Few early-stage biotech companies in the Boston area issue more than a handful of press releases every year.
But that doesn’t mean the companies and their executives aren’t keeping busy. This time last year, resTORbio (TORC) and Neon Therapeutics (NTGN) were still private companies. KSQ Therapeutics had just raised a $76 million round in October 2017 — that company just raised another $80 million this September.
About the Author Reprints
Impossible to sign up because your field boxes for personal information can’t be acessed
one year in biotech drug development is not really indicative. You should do that kind of analysis of startups that made some noise 3-5 years ago. To see if they have something to show for, bankrupted or just closed down